Am J Transplant, Volume 5, Suppl 3 Archives - Page 138 of 170 - ATC Abstracts

2015 American Transplant Congress
A Novel Signaling Approach for the Prevention of Ischemia/Reperfusion Injury (IRI)
S. Khalid,¹ M. Haller,¹ K. Koziel,¹ M. Enthammer,¹ M. Hermann,² M. Thurner,¹ L. Kremser,³ H. Lindner,³ J. Troppmair.¹
¹VTT, DSL, Innsbruck Medical University, Innsbruck, Austria; ²Anestesiology and Critical Care Medicine, Innsbruck Medical Unversity, Innsbruck, Austria; ³Division of Clinical Biochemistry, Innsbruck Medical University, Innsbruck, Austria.
Mitochondrial reactive oxygen species (ROS) produced during early reperfusion are important triggers for the development of ischemia/reperfusion injury (IRI). However, antioxidants yielded little clinical benefit…
2015 American Transplant Congress
Factors Affecting Efficacy Outcomes at 12 and 24-Months After Kidney Transplantation in Patients from the A2309 Study
C. Escrig,¹ G. Colussi,² R. Roland,² M. Vergara,³ Z. Wang.³
¹Novartis, Basel, Switzerland; ²A2309 Study Group, Basel, Switzerland; ³Novartis, East Hanover, NJ.
Purpose: Efficacy outcomes post-transplantation are influenced by donor and recipient variables and interactions between them. Here, we present data from a multivariate analysis of risk…
2015 American Transplant Congress
A 52-Week, Multicenter, Prospective, Observational, Non-Interventional, Open-Label Study to Assess the Effectiveness, Safety and Tolerability of Everolimus in Kidney Transplant Patients in Taiwan
S.-M. Wang,¹ P.-C. Lee,² J.-D. Lian,³ K.-H. Shu,⁴ S.-T. Wu,⁵ H.-C. Chen,⁶ C.-C. Huang,⁷ M.-S. Wu,⁸ Y.-C. Tian,⁹ Y.-J. Chiang,¹⁰ Y.-T. Chen,¹¹ H.-P. Wang.¹²
¹National Taiwan University Hospital, Taipei, Taiwan; ²National Cheng Kung University Hospital, Tainan, Taiwan; ³Chung Shan Medical University Hospital, Taichung, Taiwan; ⁴Taichung Veteran's General Hospital, Taichung, Taiwan; ⁵TriService General Hospital, Taipei, Taiwan; ⁶Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; ⁷China Medical University Hospital, Taichung, Taiwan; ⁸Taipei Medical University Hospital, Taipei, Taiwan; ⁹ChangGung Memorial Hospital–Taipei, Taipei, Taiwan; ¹⁰ChangGung Memorial Hospital–LinKou, Taoyuan, Taiwan; ¹¹ChangGung Memorial Hospital-Kaohsiung, Kaohsiung, Taiwan; ¹²E-Da Hospital, Kaohsiung, Taiwan.
The study aimed to assess the clinical safety and tolerability of everolimus (EVR) in Taiwan kidney transplant patients.This study enrolled 203 kidney transplant recipients, between…
2015 American Transplant Congress
Impact of Subclinical Rejection (SCR) and Acute Clinical (ACR) in Renal Transplant Recipients
R. Mehta, P. Sood, A. Cherukuri, S. Chen, G. Mour, C. Wu, N. Shah, C. Puttarajappa, P. Randhawa, A. Tevar, S. Hariharan.
University of Pittsburgh Medical Center, Pittsburgh, PA.
The importance of diagnosing subclinical rejection and its short and long term impact remains controversial.We prospectively evaluated 296 patients who had a kidney transplant at…
2015 American Transplant Congress
The use of Donation After Cardiac Death Liver Allografts does not increase Recurrence of Hepatocellular Carcinoma
K. Croome, D. Lee, J. Burns, J. Nguyen, D. Perry, D. Harnois, C. Taner.
Transplant, Mayo Clinic, Jacksonville, FL.
Background: Previous studies examining the Scientific Registry of Transplant Recipients (SRTR) database for liver transplantation (LT) have demonstrated inferior survival for hepatocellular carcinoma (HCC) recipients…
2015 American Transplant Congress
Long-Term Outcome After Liver Transplantation for Unresectable Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment
S. Radunz,¹ T. Benkoe,¹ J. Best,² A. Bockisch,³ T. Lauenstein,⁴ H. Baba,⁵ A. Paul,¹ J. Treckmann.¹
¹General, Visceral and Transplantation Surgery, University Hospital Essen, Essen, Germany; ²Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany; ³Nuclear Medicine, University Hospital Essen, Essen, Germany; ⁴Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany; ⁵Pathology and Neuropathology, University Hospital Essen, Essen, Germany.
Background: Liver transplantation remains the only curative treatment option for patients with unresectable hepatocellular carcinoma (HCC). Several bridging treatments are employed because the limited availability…
2015 American Transplant Congress
Risk Factors for Acute Cellular Rejection for Pediatric Kidney Transplant Recipients
D. Cote,¹ I. Bobanga,¹ B. Vogt,² K. Dell,² R. Cunningham III,² K. Noon,¹ V. Humphreville,¹ E. Sanchez,¹ J. Schulak,¹ K. Woodside.¹
¹Department of Surgery, Case Western Reserve University & University Hospitals, Cleveland, OH; ²Department of Pediatrics, Case Western Reserve University & University Hospitals, Cleveland, OH.
Background: Acute cellular rejection (ACR) potentially shortens the life of a kidney allograft. We sought to determine risk factors associated with the development of ACR…
2015 American Transplant Congress
Pregnancy Outcomes in Female Kidney Recipients Who Conceived Before Age 20
L. Coscia,¹ D. Armenti,¹ S. Constantinescu,² M. Moritz.¹
¹National Transplantation Pregnancy Registry, Gift of Life Institute, Philadelphia; ²Medicine, Temple University School of Medicine, Philadelphia; ³Lehigh Valley Health Network, Allentown.
The purpose of this study was to examine the pregnancy outcomes among female kidney recipients who conceived before age 20. Data were collected by the…
2015 American Transplant Congress
The Impact of Critical Illness and Pre-Transplant Hospitalization on Cost of Liver Transplantation
S. Knechtle, L. Brummett, S. Perez.
Surgery, Emory University School of Medicine, Atlanta, GA.
In order to understand the cost impact of hospitalization and ICU admission immediately prior to liver transplantation (LT), we obtained all hospital costs associated with…
2015 American Transplant Congress
Evaluation of a Three-Dose Basiliximab Induction Immunosuppression Regimen in Adult Heart Transplant Recipients
L. Donohue, W. Ally, S. Dunn, J. Kennedy, J. Bergin.
University of Virginia Health System, Charlottesville, VA.
Background: Calcineurin inhibitors (CNI) are essential agents in most orthotopic heart transplantation (OHT) anti-rejection regimens. However, nephrotoxicity limits their use in the immediate post-OHT period,…